Nkarta_Logo_2022.jpg
Nkarta to Participate in Upcoming Investor Conference
September 03, 2024 16:01 ET | Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta_Logo_2022.jpg
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 13, 2024 21:03 ET | Nkarta, Inc.
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical...
Nkarta_Logo_2022.jpg
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 13, 2024 16:01 ET | Nkarta, Inc.
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical...
Nkarta_Logo_2022.jpg
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
July 24, 2024 06:00 ET | Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that...
Nkarta_Logo_2022.jpg
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
July 16, 2024 06:01 ET | Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...
Nkarta_Logo_2022.jpg
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
June 27, 2024 06:00 ET | Nkarta, Inc.
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for...
Nkarta_Logo_2022.jpg
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
June 13, 2024 16:01 ET | Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today...
Nkarta_Logo_2022.jpg
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
May 09, 2024 16:01 ET | Nkarta, Inc.
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash...
Nkarta_Logo_2022.jpg
Nkarta to Participate in Upcoming Investor Conferences
April 03, 2024 16:02 ET | Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta_Logo_2022.jpg
Nkarta Announces Pricing of $240 Million Underwritten Offering
March 25, 2024 06:30 ET | Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the...